TY - JOUR
T1 - Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC
AU - Yoon, Hyunah
AU - Bartash, Rachel
AU - Gendlina, Inessa
AU - Rivera, Johanna
AU - Nakouzi, Antonio
AU - Bortz, Robert H.
AU - Wirchnianski, Ariel S.
AU - Paroder, Monika
AU - Fehn, Karen
AU - Serrano-Rahman, Leana
AU - Babb, Rachelle
AU - Sarwar, Uzma N.
AU - Haslwanter, Denise
AU - Laudermilch, Ethan
AU - Florez, Catalina
AU - Eugenia Dieterle, M.
AU - Jangra, Rohit K.
AU - Maximilian Fels, J.
AU - Tong, Karen
AU - Mariano, Margarette C.
AU - Vergnolle, Olivia
AU - Georgiev, George I.
AU - Herrera, Natalia G.
AU - Malonis, Ryan J.
AU - Quiroz, Jose A.
AU - Morano, Nicholas C.
AU - Krause, Gregory J.
AU - Sweeney, Joseph M.
AU - Cowman, Kelsie
AU - Allen, Stephanie
AU - Annam, Jayabhargav
AU - Applebaum, Ariella
AU - Barboto, Daniel
AU - Khokhar, Ahmed
AU - Lally, Brianna J.
AU - Lee, Audrey
AU - Lee, Max
AU - Malaviya, Avinash
AU - Sample, Reise
AU - Yang, Xiuyi A.
AU - Li, Yang
AU - Ruiz, Rafael
AU - Thota, Raja
AU - Barnhill, Jason
AU - Goldstein, Doctor Y.
AU - Uehlinger, Joan
AU - Garforth, Scott J.
AU - Almo, Steven C.
AU - Lai, Jonathan R.
AU - Gil, Morayma Reyes
AU - Fox, Amy S.
AU - Chandran, Kartik
AU - Wang, Tao
AU - Daily, Johanna P.
AU - Pirofski, Liise Anne
N1 - Publisher Copyright:
© 2021, Yoon et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
PY - 2021/2/22
Y1 - 2021/2/22
N2 - Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200 mL of CCP with a spike protein IgG titer ≥ 1:2430 (median 1:47,385) within 72 hours of admission with propensity score-matched controls cared for at a medical center in the Bronx, between April 13 and May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroid use, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared with matched controls, CCP recipients less than 65 years had 4-fold lower risk of mortality and 4-fold lower risk of deterioration in oxygenation or mortality at day 28. For CCP recipients, pretransfusion spike protein IgG, IgM, and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients less than 65 years, but data from controlled trials are needed to validate this finding and establish the effect of aging on CCP efficacy.
AB - Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200 mL of CCP with a spike protein IgG titer ≥ 1:2430 (median 1:47,385) within 72 hours of admission with propensity score-matched controls cared for at a medical center in the Bronx, between April 13 and May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroid use, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared with matched controls, CCP recipients less than 65 years had 4-fold lower risk of mortality and 4-fold lower risk of deterioration in oxygenation or mortality at day 28. For CCP recipients, pretransfusion spike protein IgG, IgM, and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients less than 65 years, but data from controlled trials are needed to validate this finding and establish the effect of aging on CCP efficacy.
UR - http://www.scopus.com/inward/record.url?scp=85101860457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101860457&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.142270
DO - 10.1172/jci.insight.142270
M3 - Article
C2 - 33476300
AN - SCOPUS:85101860457
SN - 2379-3708
VL - 6
JO - JCI Insight
JF - JCI Insight
IS - 4
M1 - e142270
ER -